LTT Bio-Pharma Co., Ltd. (E00982) Stock Price

LTT Biopharma is a drug discovery venture company whose core business is pharmaceutical research and development, and support for collaboration between Japanese and Chinese companies in the healthcare sector. The company inherited drug discovery operations from a venture spun out of St. Marianna University School of Medicine, and is built on two key technologies: a proprietary drug delivery system (DDS) and drug repositioning (DR) technology for identifying new applications of already-approved drugs. As its flagship product, the company previously developed Lipo PGE1, a lipid microparticle formulation that grew into a major pharmaceutical with sales of 5 billion yen in Japan and 4 billion yen in China.

The company's revenue structure is centered on dividend income from Beijing Tide Pharmaceutical, a major Chinese pharmaceutical company, and support service revenue from business partnerships with Sinobio, its parent company. LTT Biopharma entered into a capital and business alliance with Sinobio in 2021, and has established a system to receive monthly fixed compensation and success-based fees through supporting Japanese companies' expansion into China and pharmaceutical license brokerage services. This stable revenue base enables the company to continuously pursue high-risk drug discovery and development.

In terms of business segments, the company currently holds 11 development pipelines, with particular focus on PC-SOD, a preventive treatment for peripheral neuropathy, a side effect of anticancer drugs. The drug showed signs of efficacy in Phase 2 clinical trials, and the company is currently preparing for Phase 3 trials. In joint development with Nobel Pharma, an already-approved drug demonstrated statistically significant efficacy in Phase 3 trials for trigeminal neuralgia indication expansion, and preparations for market launch are underway.

LTT Biopharm is a drug discovery bioventure that focuses on DDS (Drug Delivery System) technology and drug repositioning research. The company aims to bring safe and beneficial pharmaceuticals to patients quickly. Its growth strategy relies on two pillars: advancing its core pipeline through R&D and generating revenue through licensing and collaborative research. Management targets include achieving operating profit and delivering stable dividends to shareholders. Currently, the company is securing R&D funding while diversifying its revenue base.

Key investment areas include preparing LT-1001 for Phase 3 clinical trials targeting chemotherapy-induced peripheral neuropathy, and preparing next-stage clinical trials for LT-5001 ahead of market launch. The company's competitive advantage lies in drug repositioning research, which identifies new therapeutic uses for already-approved drugs. Compared to developing new pharmaceuticals, this approach significantly shortens development timelines, reduces costs, and lowers failure risk.

For market expansion, the company leverages its capital and business partnerships with Beijing Tide Pharmaceutical and Sinobio to secure revenue from China operations. LTT Biopharm serves as a bridge between these partners and Japanese pharmaceutical companies, strengthening collaborative R&D and business partnerships across multiple areas. The company positions Asia market expansion as a key revenue source.

For technological innovation, the company builds cutting-edge collaborative research frameworks centered on industry-academia partnerships. It advances R&D through outsourced research and public funding. The company prioritizes risk-sharing with business partners and improving development success rates, while mobilizing the entire organization to launch new R&D initiatives. Continuous recruitment of talent strengthens R&D capabilities and maximizes organizational performance.